Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Regeneron Pharmaceuticals
Total duration per participant of approximately 43 weeks including a screening period (14-21 days), a randomized treatment period (24 weeks), and a post-treatment period (16 weeks).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with a physician diagnosis of moderate to severe, uncontrolled asthma for \>=12 months, based on the Global Initiative for Asthma (GINA) 2009 Guidelines and:
Existing treatment with moderate or high-dose inhaled corticosteroid / long-acting beta-2 agonist
Forced expiratory volume (FEV1) 40 to 80% of predicted normal
Asthma Control Questionnaire, 5-question version (ACQ-5) score \>=1.5
Reversibility of at least 12% and 200 mL in forced expiratory volume (FEV1)
Had experienced, within prior year: hospitalization, emergency or urgent care visit or systemic corticosteroid treatment for worsening asthma
You may not be if
Participants \<18 years
Chronic obstructive pulmonary disease (COPD) or other lung diseases (eg, emphysema, idiopathic pulmonary fibrosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis) which impaired pulmonary function tests
Chest X-ray within 12 months of screening visit or at screening visit with clinically significant findings of lung disease(s) other than asthma
Current smoker or cessation of smoking within 6 months prior to Visit 1
Previous smoker with a smoking history \>10 pack-years
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Clareo Health | An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
